Tübingen

• An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging p … Pending
  2023-506965-72-00 1 Parkinson Disease
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation Pending
  2024-518508-31-00 6 High risk atrial fibrillation patients with previous intracranial hemo
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 Metastatic Castrate Sensitive Prostate Cancer - mCSPC
• PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER Pending
  2025-524791-30-00 9 Non small cell lung cancer
• Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting
  2025-522455-26-00 9 2025-12-17 Acute Ischemic Stroke
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-10 … Recruiting
  2024-519128-26-00 4 2025-05-22 Non-foveal geographic atrophy secondary to non-neovascular age-related
• Safety and pharmacokinetics of antipsychotics in children 2: Studying TDM in an RCT Recruiting
  2024-511568-96-00 6 2024-07-16 Autism spectrum disorder
• Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients Recruiting
  2022-501157-36-00 6 2024-02-07 Critically ill patients who are dependent on high level medical care i
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n … Recruiting
  2023-504637-42-01 6 2023-12-21 aortic valve stenosis
• Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24) Recruiting
  2024-511264-89-00 4 2022-04-11 Glioblastoma
• EPO-TRAUMA Recruiting
  2023-506081-31-00 5 2022-03-29 Traumatic Injury
• A randomised controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (pro.LISA) Recruiting
  2024-516504-42-00 5 2022-03-05 Respiratory distress syndrome in preterm infants
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis
• Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides … Ended recruitment
  2024-517580-23-00 1 2023-03-07 Sarcoma
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• This is a study that will evaluate the safety and efficacy of TOOKAD® (padeliporfin) Vascular Targeted Photodynamic Therapy (VTP) in the Tre … Ended recruitment
  2024-512322-28-00 5 2022-10-25 Low Grade Upper Tract Urothelial Cancer

Showing 1–24 of 33 trials